Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.81 |
| ▸ | NR1H3 | Q13133 | 18/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1125098 | 0.96 | NR1H2 (0.81) | NR1H2NR1H3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1124692 | 0.90 | NR1H2 (0.95) | NR1H2NR1H3ALDH1A1HTT | |
| SCHEMBL1124681 | 0.90 | NR1H2 (1.00) | NR1H2NR1H3ALDH1A1HTT | |
| SCHEMBL6368638 | 0.90 | NR1H2 (0.78) | NR1H2NR1H3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1124578 | 0.90 | NR1H2 (0.78) | NR1H2NR1H3 | |
| SCHEMBL1124431 | 0.88 | NR1H2 (0.87) | NR1H2NR1H3 | |
| SCHEMBL1124305 | 0.88 | NR1H2 (0.87) | NR1H2NR1H3ALDH1A1HPGDHTT | |
| SCHEMBL1126112 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1124133 | 0.87 | NR1H2 (0.85) | NR1H2NR1H3ALDH1A1HPGDHTT | |
| SCHEMBL1124711 | 0.87 | NR1H2 (0.85) | NR1H2NR1H3ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | NR1H2 1/4885NR1H3 2/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.